David Moore

4 ta ish

University College London

1. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

   Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis +15

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyNew England Journal of Medicine20228 iqtibos

   ABIABI:AkademIndex/2022.article.000002

2. Population pharmacokinetics and pharmacodynamics of investigational regimens’ drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial

   Bern-Thomas Nyang’wa, Frank Kloprogge, David Moore +4

   MaqolaOAOchiq kirish20212 iqtibos

   ABIABI:AkademIndex/2026.other.006858

3. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis

   Catherine Berry, Philipp du Cros, Katherine Fielding +7

   MaqolaOAOchiq kirish20222 iqtibos

   ABIABI:AkademIndex/2026.other.133232

4. Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan

   Johanna Kuhlin, Chris Smith, Atadjan Khaemraev +8

   MaqolaTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20181 iqtibos

   ABIABI:AkademIndex/2018.article.000181